Cadherin-11 Inhibitors to Treat Poor Prognosis Cancers
Categories: “Cancer Therapeutics“
Reference #: 2009-009
OTC Contact: Ruchika Nijhara, Ph.D., MBA, CLP (Directory Information | Send a Message)
Cadherin-11, a mesenchymal cadherin associated with basal-like breast cancers and invasive cells but not expressed in normal epithelia, aligns with clinical outcome in poor prognosis cancers. The present invention describes novel compounds that inhibit Cadherin-11 and their use as potential therapeutics for poor prognosis carcinomas.
Potential therapeutics for breast cancer, prostate cancer, renal cancer, multiple myeloma, glioblastoma.
- Targeting cadherin-11 represent a novel approach to treating and diagnosing aggressive cancers
- The compounds are specific for cadherin-11-expressing cells that proliferate in difficult to treat, poor prognosis cancers
- There was no cytotoxicity observed at compound concentrations significantly above concentrations that inhibited tumor cell proliferation
- No cross reaction with other Cadherins
Stage of Development
A lead compound has been evaluated in a breast cancer model. Preliminary studies have been done to validate the target for glioblastoma multiforme (GBM). The inhibitor demonstrated high specificity for only Cadherin-11 expressing cells.
Milton L Brown, Stephen Byers, Sivanesan Dakshanamurthy and Jaime Guidry
Applications are pending